- Developing biomarkers of radioligand therapy sensitivity in locally advanced prostate cancer
- Developing novel methods to assess tumor genomic and epigenomic aberrant states using circulating tumor DNA
Our research centers on identifying genomic and epigenomic modifications in prostate cancer that contribute to metastasis and therapy resistance. We develop novel algorithms and perform genomics and functional analysis to identify clinically relevant markers for diagnostics and targets for precision therapy development. We are involved in multi-institutional collaborative research and closely interact with biostatisticians, clinicians, and translational scientists.
Current focus areas of research include developing strategies to break treatment resistance, particularly developing novel approaches to augment responses in advanced prostate cancers to DNA-damaging agents. Other major interests includes :
Design & Developed By Diligent ITech Private Limited